Updated on 26 July 2012
This patent is the fourth US patent allowance granted to Cellmid in the last nine months underpinning the company's robust intellectual property strategy in all areas of MK biology. Cellmid holds the most significant intellectual property portfolio related to MK worldwide, representing multiple product lines and commercialization opportunities.
Cellmid's patent portfolio currently includes 75 patents in 20 patent families, covering use of MK and anti-MK agents for therapeutic purposes in a number of diseases and the use of MK as a diagnostic marker in cancer and other disorders.
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
